In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pandemic Produces New Stimulus To Develop Universal Vaccine, Create Better Defenses Against Flu Mutations Of The Future

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The first pandemic to threaten the planet in decades, by focusing a global spotlight on influenza mutations and on biotech-based defenses, is creating a new stimulus to develop a universal vaccine and to expand the sectors of the worldwide populace - especially in lower-income regions - that are immunized

You may also be interested in...



Chinese Tank Commanders, Megacity Teens First In Line For A/H1N1 Vaccine

BEIJING - As the Beijing-based Sinovac Biotech ramps up production of the world's first publicly available A/H1N1 vaccine, China's Minister of Health has identified special sectors of the country's 1.3-billion-strong populace that will receive inoculations first, within the next several days

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC070129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel